Astellas v. Hetero USA: Xtandi Patent Suit Dismissed With Prejudice in 72 Days
Astellas Pharma and Medivation filed suit against Hetero USA in New Jersey District Court, asserting two patents covering enzalutamide 40 mg and 80 mg tablets — the active ingredient in blockbuster prostate cancer drug Xtandi. The case resolved in just 72 days, with all claims and counterclaims dismissed with prejudice, and each party bearing its own costs, consistent with a negotiated settlement.
Xtandi ANDA Battle Ends Swiftly in Negotiated Exit
Filed on 10 September 2025 in the District of New Jersey, this action pitted Astellas Pharma Inc., Astellas US LLC, Astellas Pharma US Inc., and Medivation LLC against generic challenger Hetero USA Inc. and its manufacturing affiliates Hetero Labs Limited and Hetero Labs Limited Unit-V. The suit centred on two US patents — US11839689B2 and US12161628B2 — both relating to enzalutamide, the active compound in Xtandi, a leading androgen receptor inhibitor prescribed for metastatic castration-resistant prostate cancer. Hetero’s ANDA filing triggered the statutory 30-month stay mechanism under Hatch-Waxman, making the litigation a high-stakes entry point for generic competition.
The case closed on 21 November 2025 — just 72 days after filing — when the court issued a dismissal order at the plaintiffs’ request. All of Astellas and Medivation’s infringement claims against Hetero were dismissed with prejudice, and all of Hetero’s counterclaims were likewise dismissed with prejudice. The court explicitly retained jurisdiction to enforce the dismissal order and the terms of an underlying settlement agreement, strongly suggesting the parties reached a private commercial resolution rather than proceeding to contested adjudication.
A 72-day resolution is notably fast for Hatch-Waxman litigation in New Jersey, where cases routinely run for two or more years before trial. The symmetric dismissal with prejudice — covering both claims and counterclaims — and the mutual cost-bearing arrangement are hallmarks of a negotiated settlement, potentially involving a licensing agreement or authorised-generic arrangement. The specific commercial terms of that settlement are not publicly disclosed in the court record, leaving the scope of any market access granted to Hetero unknown from public filings alone.
Filing to Dismissed with Prejudice in 72 days
72 days — well below the median ANDA Hatch-Waxman district court litigation timeline
Dismissed with prejudice: what the settlement-driven exit means for both parties
Dismissal with prejudice bars any re-filing on these patents
A dismissal with prejudice is a final adjudication on the merits for procedural purposes — Astellas cannot re-assert the same two patents against Hetero on the same accused products in a new action. The court’s explicit retention of jurisdiction to enforce the settlement agreement further confirms this was a consensual exit rather than a unilateral withdrawal, giving both sides a contractual enforcement mechanism beyond the litigation record.
Permanent bar on re-litigationAstellas retains patents but surrenders re-litigation rights against Hetero
US11839689B2 and US12161628B2 remain valid and in force — the dismissal carries no invalidity finding. Astellas can continue to assert these patents against other generic challengers. However, the with-prejudice dismissal means Hetero specifically cannot be sued again under these patents for the same products, suggesting Astellas extracted commercial consideration — potentially a delayed entry date or royalty — in exchange for resolving the dispute.
Patents intact; Hetero carved outHetero exits litigation but counterclaims also dismissed with prejudice
Hetero’s counterclaims — likely seeking declarations of invalidity or non-infringement — were also dismissed with prejudice. This means Hetero cannot re-litigate invalidity of these patents in a new proceeding arising from the same facts. While Hetero avoided an adverse infringement judgment, the loss of its invalidity counterclaims suggests any market entry rights were negotiated commercially, not won on the merits. An IPR petition could still be a future avenue if Hetero wishes to challenge validity.
Counterclaims extinguishedSettlement signals Xtandi patent portfolio remains a meaningful barrier
The speed of resolution — 72 days — and the symmetric with-prejudice structure suggest Astellas holds sufficient patent leverage to compel early settlement. For other generic filers targeting enzalutamide, the settlement reinforces that US11839689B2 and US12161628B2 will be actively enforced. Competitors should monitor any authorised-generic agreements or licensed entry dates that may emerge from public Orange Book listings or SEC disclosures tied to this settlement.
Active enforcement posture confirmedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Astellas Pharma, Inc. | Company | Pharmaceutical innovator and Xtandi co-developer — holder of US11839689B2 and US12161628B2Search in Eureka ↗ |
| Defendant | Hetero USA, Inc. | Company | Generic pharmaceutical manufacturer seeking ANDA approval for enzalutamide tabletsSearch in Eureka ↗ |
| Plaintiff counsel | ALEXIS M MCJOYNT | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine Clark | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | ERIN AUSTIN | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Katelyn O’Reilly | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Venable, LLP | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’reilly Falanga, LLP | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Defendant counsel | ANDREW J. KOOPMAN | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | CHRISTOPHER H. BLASZKOWSKI | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric I. Abraham | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | ERIN A. NAPOLEON | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | GRANT SCHACKELFORD | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | KARIMA TAWFKI THOMPSON | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Kristine L. Butler | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | MATTHEW J. FEDOWITZ | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | S. LLOYD SMITH | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Hill Wallack LLP | Law Firm | Representing Hetero USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal order is notable for its bilateral symmetry: every claim by Astellas and every counterclaim by Hetero is extinguished with prejudice, and neither party recovers costs. This phrasing is characteristic of a fully negotiated exit rather than a plaintiff-side capitulation. The court’s explicit retention of jurisdiction to enforce ‘the terms of the parties’ settlement agreement’ confirms a private agreement governs the commercial relationship going forward — though its terms are not disclosed in the public docket. No validity or infringement finding was made on either asserted patent.
US11839689B2 & US12161628B2 — Enzalutamide tablet formulations for prostate cancer
US11839689B2 (application no. US17/985235) and US12161628B2 (application no. US17/959350) both protect aspects of enzalutamide tablet formulations — the active pharmaceutical ingredient in Xtandi, an androgen receptor inhibitor approved for multiple stages of prostate cancer including metastatic castration-resistant and castration-sensitive disease. These are later-generation formulation patents, suggesting they may cover specific dosage forms, excipient compositions, or manufacturing processes rather than the base compound itself, which is protected by earlier foundational patents.
Xtandi has generated multi-billion-dollar annual revenues, making its patent estate a critical commercial asset for Astellas and co-owner Medivation (acquired by Pfizer). Formulation patents of this type are strategically significant because they extend effective exclusivity beyond the original compound patent expiry, creating a layered barrier to generic entry. Any generic manufacturer seeking to commercialise enzalutamide tablets in the US must conduct a thorough freedom-to-operate analysis against this patent family, as well as the broader Orange Book-listed Xtandi patent cluster.
Should you run an FTO against US11839689B2 and US12161628B2?
Any company developing, manufacturing, or seeking ANDA approval for enzalutamide 40 mg or 80 mg tablets should treat these two patents as live enforcement risks. This case demonstrates that Astellas and Medivation are willing to file suit promptly upon ANDA submission and will pursue with-prejudice resolution — indicating they view these formulation patents as commercially material, not merely defensive placeholders. R&D and regulatory teams scaling up enzalutamide formulations or filing paragraph IV certifications should prioritise FTO clearance before committing to commercialisation timelines.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of US11839689B2 and US12161628B2 against your formulation design, identify relevant prior art that could support an IPR challenge, and flag other Orange Book-listed Xtandi patents that may present parallel exposure. Eureka’s patent landscape tools also surface related family members across jurisdictions — essential for any global enzalutamide commercialisation strategy where the Xtandi patent portfolio extends to Europe, Japan, and other key markets.
Run a freedom-to-operate analysis on US11839689B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman enzalutamide patent cases in US District Courts
Explore related ANDA infringement cases involving Xtandi and enzalutamide patents in New Jersey and other US federal district courts.
What this case signals for the Xtandi and prostate cancer drug IP landscape
A 72-day settlement in a high-value ANDA case is rarely accidental — here is what the resolution pattern reveals.
Speed of settlement suggests strong Astellas patent position on enzalutamide
When a branded pharmaceutical plaintiff secures a with-prejudice dismissal in under 90 days — before substantive Markman or invalidity proceedings — it typically suggests the generic challenger assessed litigation risk as high and sought to negotiate entry terms rather than contest validity. The two patents asserted here are likely to attract further enforcement actions against other ANDA filers.
With-prejudice dismissal of Hetero’s counterclaims is a material win for Astellas
Generic challengers routinely pursue invalidity counterclaims to build leverage and create IPR-style pressure. Dismissing those counterclaims with prejudice limits Hetero’s ability to reprise that strategy in the same court. For Astellas, this preserves the patents’ enforceability profile against the broader field of enzalutamide ANDA applicants who have not yet settled.
Astellas v Hetero — key questions answered
Astellas and Medivation asserted two patents: US11839689B2 (application no. US17/985235) and US12161628B2 (application no. US17/959350), both relating to enzalutamide tablet formulations covering the 40 mg and 80 mg dosages marketed as Xtandi.
The dismissal was entered at the plaintiffs’ request and the court retained jurisdiction to enforce a settlement agreement, which strongly suggests the parties reached a private commercial resolution. A with-prejudice dismissal means neither party can re-litigate the same claims or counterclaims in a new proceeding.
A 72-day resolution is well below typical New Jersey Hatch-Waxman timelines. It suggests Hetero assessed the litigation risk as sufficiently high to negotiate early, and that Astellas’ formulation patent position was viewed as a credible enforcement threat. Other ANDA filers targeting enzalutamide should factor this precedent into their litigation risk assessments.
Yes. The dismissal with prejudice carries no invalidity finding. Both patents remain in force and can be asserted against other generic challengers. Hetero specifically is barred from being sued again on these patents for the same products, but the patents’ enforceability against third parties is unaffected.
Potentially, though the with-prejudice dismissal of Hetero’s invalidity counterclaims may create estoppel complications depending on the scope of the settlement agreement. Any IPR petition from Hetero would face scrutiny regarding whether the settlement’s terms contractually restrict future validity challenges. Other parties without such constraints remain free to file IPR petitions against these patents.
PatSnap Eureka searches patents and litigation data to answer instantly.